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Background
Determining how cross-reactive neutralizing antibody
(NAb) responses develop during natural HIV-1 infection
may provide key information to understand the role they
play in controlling the infection and in disease progres-
sion. Here we investigated the frequency and breadth of
broadly NAb responses during acute and early infection in
a well controlled cohort, and attempted to characterize
the factors associated with the development of such
responses.
Methods
The plasma of 38 clade B acutely-infected, antiretroviral-
naive subjects from two cohorts was screened for breadth
of neutralization against a panel of heterologous isolates
in an Env pseudovirus neutralization assay. Clade A, B
and C variants were chosen from reference panels of
viruses, created to evaluate the NAb responses elicited
during infection or immunization.
Results
Our preliminary screening strategy demonstrated that
broadly neutralizing antibodies can be detected in a third
of the infected subjects. Breadth of neutralization can
develop as early as one year during natural HIV infection,
however the majority of breadth was observed at over two
years post infection.
Conclusion
Cross-reactive NAbs are developed more frequently dur-
ing early infection than previously thought. The conse-
quences of this 'early' development of cross-reactive NAbs
on plasma viremia and disease progression are under
investigation.
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